Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Acute Lymphoblastic Leukemia|Adult Acute Myeloid Leukemia|Adult Burkitt Lymphoma|Adult Diffuse Large Cell Lymphoma|Adult Diffuse Mixed Cell Lymphoma|Adult Diffuse Small Cleaved Cell Lymphoma|Adult Hodgkin Lymphoma|Adult Immunoblastic Large Cell Lymphoma|Adult Lymphoblastic Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Breast Cancer|Chronic Eosinophilic Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Cutaneous T-cell Non-Hodgkin Lymphoma|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Malignant Testicular Germ Cell Tumor|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Mycosis Fungoides/Sezary Syndrome|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neutropenia|Nodal Marginal Zone B-cell Lymphoma|Ovarian Epithelial Cancer|Ovarian Germ Cell Tumor|Plasma Cell Neoplasm|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Primary Myelofibrosis|Prolymphocytic Leukemia|Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma
Interventions: DRUG: cefepime hydrochloride
Sponsor: Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)